Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
26.00    -0.75 (-2.80%)
Bid:
25.50
Ask:
26.50
Spread: 1.00 (3.922%)
Market Cap: £130.91m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading and Operational Update

31 Mar 2025 07:00

RNS Number : 7681C
Duke Capital Limited
31 March 2025
 

31 March 2025

Duke Capital Limited

 

("Duke Capital", "Duke" or the "Company")

 

Trading and Operational Update

 

Duke Capital Limited (AIM: DUKE), a leading provider of hybrid capital solutions for SME business owners in Europe and North America, is pleased to provide guidance on its trading for the fourth quarter of the financial year ending 31 March 2025 ("Q4 FY25").

 

Trading Update

 

Based on current trading, Duke expects to achieve recurring cash revenue* of £6.5 million in Q4 FY25. This represents a 12% year-on-year increase on Q4 FY24 (£5.8 million) and equal to the prior quarter, Q3 FY25, which saw the Company deliver recurring cash revenue of £6.5 million.

 

Overview of quarterly revenue growth:

 

 

Recurring Cash Revenue*

Total Cash Revenue**

Q3 FY24

£6.3 million

£6.3 million

Q4 FY24

£5.8 million

£10.2 million

Q1 FY25

£6.3 million

£6.8 million

Q2 FY25

£6.4 million

£6.8 million

Q3 FY25

£6.5 million

£6.5 million

 

* Recurring cash revenue excludes exit premium receipts and cash gains from equity sales

** Total cash revenue is monthly cash distributions from Duke's partners plus exit premium receipts and cash gains from equity sales

 

 

Operational Update

 

In February, Duke completed a £1.9 million follow-on investment into BPVA (Ireland) Limited to facilitate the acquisition of Pinta Crew Limited, an Irish consultancy business specialising in helping Irish and international organisations optimise their people, processes and resources.

 

Neil Johnson, CEO of Duke Capital, said:

 

"Despite the UK's stickier inflationary pressures, we are pleased to report that we are on track to achieve a solid year-on-year increase in recurring cash revenues for Q4 FY25. This performance reflects the strength of our business model in navigating challenging market conditions, while our follow-on investment in BPVA underscores our commitment to supporting our portfolio. With a strong balance sheet, we are confident we can deliver long-term, sustainable value for shareholders."

 

***ENDS***

 

For further information, please visit https://dukecapital.com/ or contact:

 

Duke Capital Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

+44 (0) 1481 231 816

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Stephen Keys / Callum Davidson / Michael Johnson 

+44 (0) 207 220 0500

 

Canaccord Genuity Limited

(Joint Broker)

 

Adam James / Harry Rees

+44 (0) 207 523 8000

SEC Newgate (Financial Communications)

Robin Tozer / Alice Cho / Olivia Hart

+ +44 (0) 20 3757 6882 dukecapital@secnewgate.co.uk

 

 

About Duke Capital

 

Duke is a leading provider of hybrid capital solutions for SME business owners in Europe and North America, combining the best features of both equity and debt.

 

Since 2017, Duke has provided unique long-term financing which eliminates re-financing risk and necessity for a short-term exit by providing a unique 'corporate mortgage' while also aligning its returns to grow with the success of the business.

 

Duke is focused on generating attractive risk-adjusted returns for shareholders and has a track record of achieving this across market cycles. It's three investment pillars are capital preservation, attractive dividend yield, and to provide upside upon exits.

 

Duke is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKFBQABKDNNB
Date   Source Headline
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat
6th Mar 20247:00 amRNSSuccessful Exit of Investment
4th Mar 20247:00 amRNSIncreased Equity Stake in United Glass Group
21st Feb 202411:57 amRNSName Change Effective
20th Feb 202412:08 pmRNSResult of General Meeting & Change of Name
5th Feb 20247:00 amRNSProposed Change of Name, Website and Messaging
29th Dec 20237:00 amRNSTrading Update and Follow-on Investment
19th Dec 20237:00 amRNSInterim Dividend and Dividend Declaration
29th Nov 20237:00 amRNSUpdate re. Change of Name of Nominated Adviser
22nd Nov 20237:00 amRNSFinancial Year 2024 Interim Results
21st Sep 20237:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20237:00 amRNSTrading Update
2nd Aug 20234:51 pmRNSResult of Annual General Meeting
31st Jul 20237:00 amRNSNew Royalty Agreement
28th Jul 20237:00 amRNSDirector/PDMR Dealings
20th Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
4th Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
3rd Jul 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
26th Jun 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
15th Jun 20237:00 amRNSInterim Dividend and Dividend Declaration
9th Jun 20237:00 amRNSNotice of Results
1st Jun 20237:00 amRNSTrading Update
25th May 20237:00 amRNSDirectors' Dealings
24th May 20237:00 amRNSSuccessful Exit of Investment in Royalty Partner
22nd Mar 20237:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20237:00 amRNSNew Royalty Agreement
3rd Mar 20237:00 amRNSTrading Update
21st Feb 20237:00 amRNSFollow-On Investment into Existing Royalty Partner
16th Jan 20237:00 amRNSClosing of New Credit Facility
15th Dec 20223:35 pmRNSInterim Dividend and Dividend Declaration
13th Dec 20227:00 amRNSFollow-On Investment into Existing Royalty Partner
12th Dec 20227:00 amRNSRefinance and Upsize of Credit Facility
1st Dec 20227:01 amRNSTrading Update
1st Dec 20227:00 amRNS2023 Interim Results
29th Nov 202212:38 pmRNSResult of Annual General Meeting
25th Nov 20227:00 amRNSNew Royalty Agreement
14th Nov 20227:00 amRNSNotice of AGM and Notice of Interim Results
14th Oct 20227:00 amRNSPSAs, Issue of Equity & Director/PDMR Dealings
22nd Sep 20227:00 amRNSInterim Dividend and Dividend Declaration
13th Sep 20229:09 amRNSPublication of Annual Report & Accounts
9th Sep 20227:00 amRNSPostponement of Presentation
8th Sep 20227:00 amRNSFinal Results for the year ended 31 March 2022
31st Aug 20225:04 pmRNSHolding(s) in Company
30th Aug 20223:07 pmRNSHolding(s) in Company
5th Aug 20227:00 amRNSNotice of Results and Presentations
4th Aug 20227:00 amRNSTrading Update
21st Jun 20227:00 amRNSInterim Dividend and Dividend Declaration
1st Jun 20224:25 pmRNSHolding(s) in Company
27th May 20229:08 amRNSDirector / PCA Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.